Fulgent Genetics, Inc. (FLGT)
FLGT Stock Price Chart
Explore Fulgent Genetics, Inc. interactive price chart. Choose custom timeframes to analyze FLGT price movements and trends.
FLGT Company Profile
Discover essential business fundamentals and corporate details for Fulgent Genetics, Inc. (FLGT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
29 Sept 2016
Employees
1.31K
Website
https://www.fulgentgenetics.comCEO
Ming Hsieh
Description
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
FLGT Financial Timeline
Browse a chronological timeline of Fulgent Genetics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Apr 2026
Upcoming earnings on 26 Feb 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.24.
Earnings released on 1 Aug 2025
EPS came in at $0.07 surpassing the estimated -$0.23 by +130.43%, while revenue for the quarter reached $81.80M , beating expectations by +0.46%.
Earnings released on 2 May 2025
EPS came in at $0.04 surpassing the estimated -$0.19 by +121.05%, while revenue for the quarter reached $73.46M , missing expectations by -4.57%.
Earnings released on 28 Feb 2025
EPS came in at $0.04 surpassing the estimated -$0.31 by +112.90%, while revenue for the quarter reached $76.21M , beating expectations by +1.09%.
Earnings released on 8 Nov 2024
EPS came in at $0.31 surpassing the estimated -$0.19 by +263.16%, while revenue for the quarter reached $71.74M , missing expectations by -4.84%.
Earnings released on 2 Aug 2024
EPS came in at $0.15 surpassing the estimated -$0.31 by +148.39%, while revenue for the quarter reached $71.03M , beating expectations by +2.83%.
Earnings released on 3 May 2024
EPS came in at -$0.01 surpassing the estimated -$0.33 by +96.97%, while revenue for the quarter reached $64.49M , missing expectations by -1.34%.
Earnings released on 28 Feb 2024
EPS came in at $0.28 surpassing the estimated -$0.30 by +193.33%, while revenue for the quarter reached $70.51M , beating expectations by +6.31%.
Earnings released on 3 Nov 2023
EPS came in at -$0.39 falling short of the estimated -$0.32 by -21.88%, while revenue for the quarter reached $84.69M , beating expectations by +26.13%.
Earnings released on 4 Aug 2023
EPS came in at -$0.08 surpassing the estimated -$0.33 by +75.76%, while revenue for the quarter reached $67.85M , beating expectations by +8.60%.
Earnings released on 5 May 2023
EPS came in at -$0.22 surpassing the estimated -$0.45 by +51.11%, while revenue for the quarter reached $66.17M , beating expectations by +10.19%.
Earnings released on 28 Feb 2023
EPS came in at -$0.48 surpassing the estimated -$0.56 by +14.29%, while revenue for the quarter reached $67.70M , beating expectations by +13.66%.
Earnings released on 7 Nov 2022
EPS came in at $0.32 surpassing the estimated $0.17 by +88.24%, while revenue for the quarter reached $105.66M , beating expectations by +15.65%.
Earnings released on 4 Aug 2022
EPS came in at $0.78 surpassing the estimated $0.73 by +6.85%, while revenue for the quarter reached $125.34M , beating expectations by +2.15%.
Earnings released on 3 May 2022
EPS came in at $5.08 surpassing the estimated $3.86 by +31.61%, while revenue for the quarter reached $320.27M , beating expectations by +18.25%.
Earnings released on 23 Feb 2022
EPS came in at $3.34 surpassing the estimated $2.61 by +27.97%, while revenue for the quarter reached $251.67M , beating expectations by +31.70%.
Earnings released on 9 Nov 2021
EPS came in at $3.95 surpassing the estimated $3.25 by +21.54%, while revenue for the quarter reached $227.87M , beating expectations by +72.68%.
Earnings released on 9 Aug 2021
EPS came in at $2.47 falling short of the estimated $2.76 by -10.51%, while revenue for the quarter reached $153.62M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at $6.59 surpassing the estimated $5.86 by +12.46%, while revenue for the quarter reached $359.43M , beating expectations by +12.69%.
Earnings released on 4 Mar 2021
EPS came in at $6.20 surpassing the estimated $4.05 by +53.09%, while revenue for the quarter reached $294.98M .
Earnings released on 9 Nov 2020
EPS came in at $2.08 surpassing the estimated $0.55 by +278.18%, while revenue for the quarter reached $101.72M , missing expectations by -37.64%.
FLGT Stock Performance
Access detailed FLGT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.